Your browser doesn't support javascript.
loading
Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis.
Chen, Minshan; Lai, Yuanqiang; Chen, Riken; Lu, Jianmin; Zhang, Yu; Liu, Haimin; Wang, Donghao; Zhong, Yue; Zheng, Zhenzhen; Hong, Cheng.
Affiliation
  • Chen M; China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China; Department of Clinical Medicine, The First Clinical School of Guangzhou Medical University, China.
  • Lai Y; China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China; Department of Clinical Medicine, The First Clinical School of Guangzhou Medical University, China.
  • Chen R; China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China.
  • Lu J; China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China.
  • Zhang Y; China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China.
  • Liu H; China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China.
  • Wang D; China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China.
  • Zhong Y; China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China.
  • Zheng Z; Department of Respiration, The Second Affiliated Hospital of Guangdong Medical University, China. Electronic address: 3342227603@qq.com.
  • Hong C; China State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China. Electronic address: gyfyyhc@126.com.
Pulm Pharmacol Ther ; 72: 102100, 2022 02.
Article in En | MEDLINE | ID: mdl-34856365
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Epoprostenol / Hypertension, Pulmonary / Antihypertensive Agents Type of study: Clinical_trials / Systematic_reviews Limits: Humans Language: En Journal: Pulm Pharmacol Ther Journal subject: FARMACOLOGIA Year: 2022 Document type: Article Affiliation country: China Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptors, Epoprostenol / Hypertension, Pulmonary / Antihypertensive Agents Type of study: Clinical_trials / Systematic_reviews Limits: Humans Language: En Journal: Pulm Pharmacol Ther Journal subject: FARMACOLOGIA Year: 2022 Document type: Article Affiliation country: China Country of publication: Reino Unido